Therapeutic Advances in Neurological Disorders (Jul 2023)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4

  • Diego Centonze,
  • Maria Pia Amato,
  • Vincenzo Brescia Morra,
  • Eleonora Cocco,
  • Nicola De Stefano,
  • Claudio Gasperini,
  • Paolo Gallo,
  • Carlo Pozzilli,
  • Maria Trojano,
  • Massimo Filippi

DOI
https://doi.org/10.1177/17562864231183221
Journal volume & issue
Vol. 16

Abstract

Read online

Multiple sclerosis (MS) is a chronic, progressive neurological disease involving neuroinflammation, neurodegeneration, and demyelination. Cladribine tablets are approved for immune reconstitution therapy in patients with highly active relapsing–remitting MS based on favorable efficacy and tolerability results from the CLARITY study that have been confirmed in long-term extension studies. The approved 4-year dosing regimen foresees a cumulative dose of 3.5 mg/kg administered in two cycles administered 1 year apart, followed by 2 years of observation. Evidence on managing patients beyond year 4 is scarce; therefore, a group of 10 neurologists has assessed the available evidence and formulated an expert opinion on management of the growing population of patients now completing the approved 4-year regimen. We propose five patient categories based on response to treatment during the first 4-year regimen, and corresponding management pathways that envision close monitoring with clinical visits, magnetic resonance imaging (MRI) and/or biomarkers. At the first sign of clinical or radiological disease activity, patients should receive a highly effective disease-modifying therapy, comprising either a full cladribine regimen as described in regulatory documents (cumulative dose 7.0 mg/kg) or a comparably effective treatment. Re-treatment decisions should be based on the intensity and timing of onset of disease activity, clinical and radiological assessments, as well as patient eligibility for treatment and treatment preference.